Treatment of Venous Thromboembolism in Cancer Patients

Silverstein M. , Heit J. , Mohr D. . Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 4: 585–593.

Heit J. , Silverstein M. , Mohr D. . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 4: 809–815.

Blom J.W. , Doggen C.J. , Osanto S. . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 4: 715–722.

Hutten B. , Prins M. , Gent M. . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000; 4: 3078–3083.

Prandoni P. , Lensing A.W. , Piccioli A. . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100: 3484–3488.

Sorensen H.T. , Mellemkjaer L. , Olsen J.H. . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 4: 1846–1850.

Baron J.A. , Gridley G. , Weiderpass E. . Venous thromboembolism and cancer. Lancet. 1998; 4: 1077–1080.

Rickles F.R. , Edwards R.L. . Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983; 4: 14–31.

Levine M.N. , Lee A.Y. , Kakkar A.K. . From Trousseau to targeted therapy: insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003; 1: 1456–1463.

Buller H.R. , Agnelli G. , Hull R.D. . Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 401S–428S.

van Dongen C.J.J. , van den Belt A.G.M. , Prins M.H. . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. The Cochrane Database of Systematic Reviews. 2004, Issue 4.

Weitz J.I. . Low-molecular-weight heparins. N Engl J Med. 1997; 4: 688–698.

Warkentin T.E. , Levine M.N. , Hirsh J. . Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 4: 1330–1335.

Lee A.Y.Y. . Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2004; 4: 291–302.

Levine M. , Gent M. , Hirsh J. . A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 4: 677–681.

Koopman M. , Prandoni P. , Piovella F. . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996; 4: 682–687.

The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997; 334: 657–662.

Merli G. , Spiro T. , Olsson C. . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001; 4: 191–202.

Ansell J. , Hirsh J. , Poller L. . The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl): 204S–233S.

Lee A. , Levine M. , Baker R. . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 4: 146–153.

Meyer G. , Marjanovic Z. , Valcke J. . Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 4: 1729–1735.

Das S.K. , Cohen A.T. , Edmondson R.A. . Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996; 4: 521–526.

Lee A.Y.Y. , Rickles F.R. , Julian J.A. . Randomized comparison low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 4: 2123–2129.

Klerk C.P. , Smorenburg S.M. , Otten H.M. . The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 4: 2130–2135.

Nightingale S.L. . From the Food and Drug Administration. JAMA. 1993: 270: 1672.

Noble S.I.R. , Finlay I.G. . Is long-term LMWH acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med. 2005; 4: 1–5.